A study, published in Cancer Biotherapy and Radiopharmaceuticals, examined new biological drugs which treat metastatic colorectal cancer.
Here's what you should know:
1. Bevacizumab, aflibercept, regorafenib, cetuximab and panitumumab have all been approved by the FDA for the treatment of metastatic colorectal cancer.
2. The new study shows these drugs increase median overall survival by up to more than 40 months when used in combination with traditional chemotherapy.
3. The FDA approved Cetuximab in 2004. It was the first biologic drug the FDA approved.
4. Researchers are in the process of conducting more studies on the combination therapies. They believe combination therapy will "become a standard care to improve patients' life."
More articles on gastroenterology:
Stock market week-in-review for 5 large GI companies — Aug. 21-25
GI center to know: Associated Endoscopy
GI leader to know: Dr. G. Whit James of Associates in Gastroenterology